C-Reactive Protein and Its Relationship with Pain in Patients with Advanced Cancer Cachexia: Secondary Cross-Sectional Analysis of a Multicenter Prospective Cohort Study

Koji Amano, MD,1,2,*, Hiroto Ishiki, MD,1 Tomofumi Miura, MD, PhD,3,4 Isseki Maeda, MD, PhD,4,5 Yutaka Hatano, MD, PhD,6 Shunsuke Oyamada, MSc,6 Naosuke Yokomichi, MD, PhD,7 Keita Tagami, MD, PhD,8,† Takuya Odagiri, MD, MD, PhD,9 Tetsuya Ito, MD, PhD,10 Mika Baba, MD, PhD,11 Keita Tagami, MD, PhD,11 Tatsuya Morita, MD,7 and Masanori Mori, MD7; on behalf of the East-Asian Collaborative Cross-Cultural Study to Elucidate the Dying Process (EASED) Investigators**

Abstract

**Background:** Limited information is available on the relationship between C-reactive protein (CRP) levels and pain in advanced cancer.

**Objectives:** To investigate the relationship between serum levels of CRP and subtypes of pain.

**Design:** A secondary cross-sectional analysis of a prospective cohort study.

**Setting/Subjects:** Patients with advanced cancer admitted to 23 palliative care units in Japan.

**Measurements:** Patients rated the severity of pain on the numerical rating scale (NRS) and physicians evaluated pain on the integrated palliative care outcome scale (IPOS). Physicians assessed neuropathic pain and breakthrough pain based on their presence or absence. Patients were divided into four groups according to CRP levels. Comparisons were performed using the Kruskal–Wallis test or chi-squared test. To evaluate the relationship between CRP and subtypes of pain, adjusted odds ratios (ORs) and 95% confidence intervals (CIs) in logistic models were calculated.

**Results:** We divided 1513 patients into four groups: low CRP (n = 234), moderate CRP (n = 513), high CRP (n = 352), and very high CRP (n = 414). Spearman's correlation coefficient between CRP and pain NRS and that between CRP and pain IPOS were 0.15 (p < 0.001) and 0.16 (p < 0.001), respectively. In the models of pain NRS...
and pain IPOS, significantly higher adjusted ORs than in the low CRP group were observed in the very high CRP group (1.81 [95% CI 1.14–2.88], \(p=0.01\); 1.74 [95% CI 1.18–2.57], \(p=0.005\), respectively). Relationships were not observed between CRP, neuropathic pain, and breakthrough pain.

**Conclusions:** The results indicated direct relationships between CRP, pain NRS, and pain IPOS.

**Keywords:** advanced cancer; cancer cachexia; C-reactive protein; pain; palliative care

---

**Introduction**

Accumulating evidence suggests that systemic inflammation and inflammation in the tumor microenvironment are some of the mechanisms underlying cancer cachexia.\(^1\)\(^-\)\(^6\) Pain and other symptoms, such as anorexia, fatigue, drowsiness, depression, anxiety, and delirium, have frequently been detected under conditions in which a systemic inflammatory response occurs in patients with advanced cancer.\(^7\)\(^-\)\(^14\) Furthermore, serum levels of C-reactive protein (CRP) have been identified as a surrogate of systemic inflammation related to survival, the activities of daily living, physical symptoms, and psychological symptoms.\(^7\)\(^-\)\(^14\) A large prospective cohort study reported that the positive rates of symptoms increased as CRP levels became higher.\(^11\) It also showed that the rates of positivity for anorexia and fatigue were 80%–90% in patients with very high CRP levels.\(^11\) Another prospective cohort study revealed that the incidence of drowsiness and delirium significantly increased as CRP levels became higher.\(^14\) In addition, two studies showed that CRP levels were related to pain with a comprehensive evaluation in advanced cancer,\(^7\)\(^,\)\(^8\) whereas the same group also reported a relationship between these two variables.\(^10\)\(^,\)\(^15\)

Therefore, to the best of our knowledge, limited information is currently available on the relationship between elevated CRP levels and pain in patients with cancer cachexia. Furthermore, it has not yet been established whether relationships exist between elevated CRP levels and several subtypes of pain, including nociceptive pain, neuropathic pain, and breakthrough pain, even though pain is the most common symptom in patients with advanced cancer receiving palliative care.

Therefore, we conducted a secondary analysis of a prospective cohort study in palliative care units across Japan to investigate the relationships between CRP levels and subtypes of pain. We also examined the current implementation of opioid medications for cancer pain among groups according to CRP levels because opioids may be a confounding factor in the relationship between CRP levels and pain.

**Materials and Methods**

**Sites and participants**

This study was a secondary cross-sectional analysis of a large multicenter prospective cohort study, which was conducted at 23 palliative care units in Japan between January 2017 and June 2018. In brief, consecutive patients who had been newly referred to these palliative care units were enrolled. All patients were followed up to their death or six months after enrollment. All institutions consecutively obtained a sample of data, up to the designated number of patients of 50, 60, 70, 80, 100, 150, and 250 according to the size of the institution. Inclusion criteria were (1) adult patients (18 years or older), (2) patients with locally advanced or metastatic cancer (including hematological neoplasms), and (3) patients admitted to palliative care units. Patients who planned to be discharged within one week or those who did not want to participate were excluded from this study.

This study was conducted in accordance with the ethical standards of the Declaration of Helsinki and ethical guidelines for epidemiological research presented by the Ministry of Health, Labour, and Welfare in Japan. The study was approved by the local institutional review boards of all participating institutions. Since Japanese law does not require individual informed consent from participants in a noninvasive observational trial, we used an opt-out method rather than acquiring written or oral informed consent.

**Measurements**

Patient characteristics (age, gender, primary cancer site, the presence of metastasis, chemotherapy or targeted therapy within one month, and the Eastern Cooperative Oncology Group Performance Status [ECOG PS])\(^16\) were obtained at baseline.

Palliative care physicians asked patients to rate the severity of pain with a comprehensive evaluation on the numerical rating scale (NRS) ranging between 0 (not at all) and 10 (overwhelming), and the Eastern Cooperative Oncology Group Performance Status (ECOG PS)\(^16\) was obtained at baseline.

Palliative care physicians asked patients to rate the severity of pain with a comprehensive evaluation on the numerical rating scale (NRS) ranging between 0 (not at all) and 10 (overwhelming), and physicians also evaluated the integrated palliative care outcome scale (IPOS)\(^17\) ranging between 0 (not at all) and 4 (overwhelming) at baseline. They assessed neuropathic
pain and breakthrough pain according to the Clinical Guidelines for Cancer Pain Management edited by the Japanese Society for Palliative Medicine based on their presence or absence at baseline.

The types of opioids, administration routes of opioids, and opioid oral morphine milligram equivalent (mg/day) were recorded by palliative care physicians at baseline. Laboratory data (serum levels of albumin and CRP) measured within seven days before admission or three days after admission were also recorded. Survival was defined as the time from admission to a palliative care unit to death or discharge. Patients being discharged had been followed up for six months from baseline.

Statistical analysis

Patient characteristics are shown as a mean ± standard deviation, median (interquartile range), or as a n (%) where appropriate. Patients were divided into four groups according to CRP levels: (1) low (CRP <1 mg/dL), (2) moderate (1 ≤ CRP <5 mg/dL), (3) high (5 ≤ CRP <10 mg/dL), and (4) very high (10 mg/dL ≤ CRP). We used approximate figures to quartile points, as described in our previous studies, which indicated the utility of CRP for predicting survival, the activities of daily living, physical symptoms, and psychological symptoms in patients with advanced cancer.

Comparisons among the groups were performed using the Kruskal–Wallis test or chi-squared test where appropriate. Spearman’s correlation coefficients between pain NRS and pain IPOS and between CRP and pain were calculated to assess the relationship between two variables using a monotonic function; Spearman’s correlation coefficient: <0.2 poor agreement, 0.21–0.4 fair, 0.41–0.6 moderate, 0.61–0.8 good, 0.81–0.99 very good, and 1 perfect.

To evaluate the relationship between the four CRP groups, pain NRS (0–3 or 4–10), pain IPOS (0–1 or 2–4),21 neuropathic pain (presence or absence), and breakthrough pain (presence or absence), adjusted odds ratios (ORs), and 95% confidence intervals (CIs) were calculated after adjustments for independent variables known as potential risk factors for the development of pain in cancer patients, such as age, gender, metastasis, chemotherapy or targeted therapy within one month, ECOG PS, and the opioid oral morphine milligram equivalent.

They were entered into the logistic model using the forced entry method. We sequentially introduced variables into the model. Demographic and biological variables were followed by the opioid dose to clarify the influence of opioids as a confounding factor on the effects of other factors for pain. All results were considered to be significant when the p-value was <0.05. All analyses were performed using SPSS software version 22.0 (SPSS, Inc., Chicago, IL).

Results

Among the original cohort of 1896 patients, 383 were excluded due to missing data on main outcome variables, such as CRP, pain NRS, and pain IPOS. Therefore, 1513 patients (79.8%) were considered to be eligible for analyses.

Patient characteristics are summarized in Table 1. Mean age was 72.5 ± 12.2 years, and the percentage of male patients was 50.5%. The top three sites of primary cancer were the upper and lower gastrointestinal tract, the liver/biliary system/pancreas, and the lungs. The percentage of patients with metastasis was 84.9%. The percentage of patients receiving chemotherapy or targeted therapy within one month was 9.2%. The percentages of patients with ECOG PS 3 and 4 were 46.3% and 44.4%, respectively. Mean serum levels of albumin and CRP were 2.5 ± 0.7 g/dL and 7.5 ± 7.3 mg/dL, respectively. The median actual survival time was 20.0 (9.0–43.0) days.

| Table 1. Patient Characteristics (n = 1513) |
|-------------------------------------------|
| Age in years, mean (SD)                  | 72.5 (12.2) |
| Gender, n (%)                            |            |
| Male                                     | 764 (50.5)  |
| Female                                   | 749 (49.5)  |
| Primary cancer site, n (%)               |            |
| Upper and lower gastrointestinal tract   | 421 (27.8)  |
| Liver, biliary system, and pancreas      | 294 (19.4)  |
| Lung                                     | 243 (16.1)  |
| Urological                               | 115 (7.6)   |
| Breast                                   | 108 (7.1)   |
| Gynecological                            | 94 (6.2)    |
| Head and neck                            | 62 (4.1)    |
| Hematological                            | 42 (2.8)    |
| Others                                   | 134 (8.9)   |
| Metastasis, yes, n (%)                   | 1285 (84.9) |
| Chemotherapy or targeted therapy         | 139 (9.2)   |
| within one month, yes, n (%)             |            |
| ECOG PS, n (%)                           |            |
| 0–1                                      | 20 (1.3)    |
| 2                                        | 121 (8.0)   |
| 3                                        | 700 (46.3)  |
| 4                                        | 672 (44.4)  |
| Serum levels, mean (SD)                  |            |
| Albumin (g/dL)                           | 2.5 (0.7)   |
| CRP (mg/dL)                              | 7.5 (7.3)   |
| Survival time (days), median (IQR)       | 20.0 (9.0–43.0) |

Values are means ± SD, median (IQR), or n (%). CRP, C-reactive protein; ECOG PS, Eastern Cooperative Oncology Group performance status; IQR, interquartile range; SD, standard deviation.
Table 2. Prevalence and Use of Opioids According to C-Reactive Protein Levels

| Types of opioids, n (%) | Total (n = 1513) | CRP <1 mg/dL (n = 234) | 1 ≤ CRP <5 mg/dL (n = 513) | 5 ≤ CRP <10 mg/dL (n = 352) | 10 ≤ CRP (n = 414) |
|------------------------|------------------|------------------------|--------------------------|----------------------------|-------------------|
| None | 526 (34.8) | 117 (50.0) | 203 (39.6) | 104 (29.5) | 102 (24.6) |
| Morphine | 291 (19.2) | 36 (15.4) | 88 (17.2) | 71 (20.2) | 96 (23.2) |
| Oxycodone | 412 (27.2) | 42 (17.9) | 121 (23.6) | 108 (30.7) | 141 (34.1) |
| Fentanyl | 244 (16.1) | 32 (13.7) | 85 (16.6) | 56 (15.9) | 71 (17.1) |
| Tramadol | 44 (2.9) | 7 (3.0) | 17 (3.3) | 10 (2.8) | 10 (2.4) |
| Codeine, tapentadol, hydromorphone, or methadone | 42 (2.8) | 6 (2.6) | 13 (2.5) | 14 (4.0) | 9 (2.2) |

Administration routes of opioids, n (%)

| Opioid oral morphine milligram equivalent (mg/day), mean (SD) | Total (n = 1513) | CRP <1 mg/dL (n = 234) | 1 ≤ CRP <5 mg/dL (n = 513) | 5 ≤ CRP <10 mg/dL (n = 352) | 10 ≤ CRP (n = 414) |
|------------------------|------------------|------------------------|--------------------------|----------------------------|-------------------|
| Oral | 45.5 (90.6) | 24.8 (47.8) | 41.3 (75.7) | 60.5 (134.2) | 49.5 (76.6) |
| Patch | 340 (22.5) | 51 (21.8) | 112 (21.8) | 87 (24.7) | 90 (21.7) |
| Subcutaneous or intravenous | 320 (27.9) | 46 (19.6) | 143 (27.9) | 129 (36.6) | 182 (44.0) |
| Suppository or buccal | 39 (0.6) | 1 (0.4) | 4 (0.8) | 1 (0.3) | 3 (0.7) |

The sums of some percentages were >100% because of the concurrent use of two or more types of opioids.

We then divided patients into four groups according to CRP levels: (1) low (CRP <1 mg/dL) (n = 234), (2) moderate (1 ≤ CRP <5 mg/dL) (n = 513), (3) high (5 ≤ CRP <10 mg/dL) (n = 352), and (4) very high (10 mg/dL ≤ CRP) (n = 414).

The current implementation of opioid medications for cancer pain is given in Table 2. The average percentage of patients reporting any opioid use was 65.2%, which increased as CRP levels became higher. Regarding the administration routes of opioids, a subcutaneous or intravenous route was the most frequent (33.1%) in all patients, and reached 44.0% in the high CRP group. The mean value of the opioid oral morphine milligram equivalent in all patients and in the high CRP group (5 ≤ CRP <10 mg/dL) were 45.5 ± 90.6 mg/day and 60.5 ± 134.2 mg/day, respectively. The mean value of the opioid oral morphine milligram equivalent in the high CRP group was the highest among the four groups categorized according to CRP levels (Table 2).

Spearman’s correlation coefficient between pain NRS and pain IPOS was 0.66 (p < 0.001). The relationships between CRP and pain are given in Table 3. Spearman’s correlation coefficient between CRP and pain NRS and that between CRP and pain IPOS were 0.15 (p < 0.001) and 0.16 (p < 0.001), respectively. The proportions of pain NRS (4–10) and pain IPOS (2–4) and the positive rates of neuropathic pain and breakthrough pain in the four CRP groups are also summarized in Table 3. The proportions of pain NRS (4–10) and pain IPOS (2–4) significantly increased as CRP levels became higher (p < 0.001), whereas the positive rates of neuropathic pain and breakthrough pain did not significantly change.

Adjusted ORs for CRP and other variables associated with pain NRS and pain IPOS are given in Tables 4 and 5, respectively. Six variables other than the opioid oral morphine milligram equivalent were included in model 1, whereas seven were included in model 2. In model 1 of pain NRS, there were significant differences in the adjusted ORs between the low CRP group and the high CRP and very high CRP groups (1.64 [95% CI 1.04–2.57], p = 0.03; 2.34 [95% CI 1.51–3.62], p < 0.001, respectively). In model 2 of pain NRS, there was a significant difference in the adjusted OR between the low CRP group and the very high CRP group (1.81 [95% CI 1.14–2.88], p = 0.01) (Table 4).

Table 3. Relationships Between C-Reactive Protein Levels and Pain

| Pain NRS, median (IQR) | Total (n = 1513) | CRP <1 mg/dL (n = 234) | 1 ≤ CRP <5 mg/dL (n = 513) | 5 ≤ CRP <10 mg/dL (n = 352) | 10 ≤ CRP (n = 414) |
|------------------------|------------------|------------------------|--------------------------|----------------------------|-------------------|
| Yes | 320 (27.9) | 39 (20.1) | 88 (23.8) | 78 (29.2) | 115 (36.2) |
| No | 125 (10.9) | 16 (6.9) | 33 (6.5) | 24 (6.8) | 31 (7.8) |
| Pain IPOS, median (IQR) | 565 (37.4) | 62 (26.5) | 175 (34.1) | 139 (39.5) | 189 (45.8) |
| Yes | 211 (14.0) | 31 (13.4) | 63 (12.3) | 51 (14.5) | 66 (15.9) |
| No | 601 (40.9) | 82 (35.3) | 191 (37.4) | 145 (41.2) | 183 (44.2) |

Comparisons among groups were performed using the Kruskal–Wallis test or chi-squared test where appropriate. IPOS, integrated palliative care outcome scale; NRS, numerical rating scale.
However, in model 1 of pain IPOS, there were significant differences in the adjusted ORs between the low CRP group and the moderate CRP, high CRP, and very high CRP groups (1.49 [95% CI 1.05–2.12], \( p = 0.03 \); 1.82 [95% CI 1.26–2.64], \( p = 0.002 \); 2.31 [95% CI 1.61–3.33], \( p < 0.001 \), respectively). In model 2 of pain IPOS, there was a significant difference in the adjusted OR between the low CRP group and the very high CRP group (1.74 [95% CI 1.18–2.57], \( p = 0.005 \)) (Table 5).

To evaluate the relationship between the four CRP groups and pain NRS (0–3 or 4–10), ORs and 95% CIs were calculated after adjustments for independent variables, such as age, gender, metastasis, chemotherapy, or targeted therapy within one month, the ECOG PS, and the opioid oral morphine milligram equivalent.

### Discussion

To the best of our knowledge, this is the first large cross-sectional study to report relationships between CRP levels and pain, particularly subtypes of pain, in patients with advanced cancer admitted to palliative care units who had a survival time of days to weeks. The majority of patients in this study may have been at the stage of refractory cachexia from the viewpoint of survival, because the median actual survival time was 20.0 days.\(^2\) The results obtained demonstrated that pain positively correlated with CRP levels in this population.

The results of this study indicate that pain, except for neuropathic pain and breakthrough pain, was associated with CRP levels. Increases in CRP levels were associated with the worsening of pain NRS and pain IPOS. Nevertheless, it is important to note that pain NRS and pain IPOS may collectively comprise nociceptive pain, neuropathic pain, and breakthrough pain.

Although Spearman’s correlation coefficients were weak and statistically significant in the context of the large sample size, correlations remained in logistic models.

| Table 4. Odds Ratios of Pain Numerical Rating Scale (4–10) by C-Reactive Protein Levels (n = 1148) |
|---------------------------------------------------------------|
| **Crude OR (95% CI)**                                    | **Adjusted OR (95% CI)** | **Adjusted OR (95% CI)** |
| **Model 1**                                                   | **Model 2** | **Model 1** | **Model 2** | **Model 1** | **Model 2** |
| CRP (mg/dL)                                           |              |              |              |              |              |
| CRP <1                                                  | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| 1 ≤ CRP <5                                              | 1.25 (0.81–1.90) | 1.27 (0.82–1.95) | 1.10 (0.70–1.74) | 0.69 |
| 5 ≤ CRP <10                                             | 1.64 (1.06–2.55) | 1.64 (1.04–2.57) | 1.29 (0.80–2.07) | 0.30 |
| 10 ≤ CRP                                                | 2.25 (1.48–3.42) | 2.34 (1.51–3.62) | 1.81 (1.14–2.88) | 0.01 |

Opioids (mg/day)

| 0                                        |              |              |              |              |              |
| 0–60                                      |              |              |              |              |              |
| 60≤                                       |              |              |              |              |              |

To evaluate the relationship between the four CRP groups and pain NRS (0–3 or 4–10), ORs and 95% CIs were calculated after adjustments for independent variables, such as age, gender, metastasis, chemotherapy or targeted therapy within one month, the ECOG PS, and the opioid oral morphine milligram equivalent.

### Table 5. Odds Ratios of Pain Integrated Palliative Care Outcome Scale (2–4) by C-Reactive Protein Levels (n = 1512)

| **Crude OR (95% CI)** | **Adjusted OR (95% CI)** | **Adjusted OR (95% CI)** | **Adjusted OR (95% CI)** |
|-----------------------|-------------------------|-------------------------|-------------------------|
| **Model 1**           | **Model 2** | **Model 1** | **Model 2** | **Model 1** | **Model 2** |
| CRP (mg/dL)            |              |              |              |              |              |
| CRP <1                 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| 1 ≤ CRP <5             | 1.44 (1.02–2.02) | 1.49 (1.05–2.12) | 1.27 (0.87–1.85) | 0.21 |
| 5 ≤ CRP <10            | 1.81 (1.26–2.60) | 1.82 (1.26–2.64) | 1.37 (0.92–2.03) | 0.12 |
| 10 ≤ CRP               | 2.34 (1.65–3.32) | 2.31 (1.61–3.33) | 1.74 (1.18–2.57) | 0.005 |

Opioids (mg/day)

| 0                       |              |              |              |              |              |
| 0–60                    |              |              |              |              |              |
| 60≤                     |              |              |              |              |              |

To evaluate the relationship between the four CRP groups and pain NRS (0–3 or 4–10), ORs and 95% CIs were calculated after adjustments for independent variables, such as age, gender, metastasis, chemotherapy or targeted therapy within one month, the ECOG PS, and the opioid oral morphine milligram equivalent.
However, the influence of opioids as a confounding factor on the effects of other factors for pain cannot be ignored. A high CRP level (5 ≤ CRP < 10 mg/dL) was significant in model 1, but not in model 2 for both pain NRS and pain IPOS. However, we previously reported that high CRP levels were associated not only with poor survival and deteriorations in the activities of daily living, but also with impaired consciousness.9,11,14 This result suggests that patients categorized into the very high CRP group may be almost bedridden due to deteriorations in the activities of daily living and impaired consciousness and that pain may not be as severe as that in the high CRP group, which is supported by the dose of opioids in the high CRP group being the highest among the four groups examined.

After controlling for the confounding influence of opioids, a correlation was only observed between the very high CRP level (10 mg/dL ≤ CRP) and pain NRS and pain IPOS. This suggests a relationship with the threshold between CRP and pain. Furthermore, the present results are consistent with previous findings showing relationships between systemic inflammation measured using serum levels of CRP and pain in advanced cancer.7,8 However, both studies used a univariate correlation analysis and showed a very weak correlation between CRP and pain, which may have been due to the large sample size.

Relationships between CRP levels, neuropathic pain, and breakthrough pain were not observed in this study. Neuropathic pain is caused by direct damage to the nervous system from a primary tumor, metastases, or cancer treatment, such as chemotherapy. A nerve may be infiltrated or compressed by a tumor or strangulated by fibrosis.22–26 Inflammation in the tumor microenvironment may affect the surrounding nerves, but systemic inflammation is not always necessary in the genesis of neuropathic pain.

### Table 6. Odds Ratios of Neuropathic Pain by C-Reactive Protein Levels (n = 1509)

| CRP (mg/dL)    | Univariate analysis | Multivariate analysis |
|----------------|---------------------|-----------------------|
|                | Crude OR (95% CI)   | p                     | Adjusted OR (95% CI)   | p   |
|                | 1.00 (reference)    | 0.70                  | 1.00 (reference)       | 0.73 |
| 1 ≤ CRP <5     | 0.91 (0.58–1.45)    | 0.70                  | 0.92 (0.58–1.47)       | 0.73 |
| 5 ≤ CRP <10    | 1.10 (0.68–1.78)    | 0.70                  | 1.05 (0.64–1.72)       | 0.60 |
| 10 ≤ CRP       | 1.23 (0.78–1.95)    | 0.38                  | 1.14 (0.71–1.83)       | 0.60 |

| Opioids (mg/day) | Univariate analysis | Multivariate analysis |
|------------------|---------------------|-----------------------|
|                  |                     |                       |                       |
| 0                | —                   | —                     | 1.00 (reference)      |      |
| 0–60             | —                   | —                     | 3.70 (2.30–5.93)      | <0.001|
| ≥ 60             | —                   | —                     | 6.43 (3.90–10.58)     | <0.001|

To evaluate the relationship between the four CRP groups and neuropathic pain (presence or absence), ORs and 95% CIs were calculated after adjustments for independent variables, such as age, gender, metastasis, chemotherapy or targeted therapy within one month, the ECOG PS, and the opioid oral morphine milligram equivalent.

### Table 7. Odds Ratios of Breakthrough Pain by C-Reactive Protein Levels (n = 1509)

| CRP (mg/dL)    | Univariate analysis | Multivariate analysis |
|----------------|---------------------|-----------------------|
|                | Crude OR (95% CI)   | p                     | Adjusted OR (95% CI)   | p   |
|                | 1.00 (reference)    | 0.70                  | 1.00 (reference)       | 0.73 |
| 1 ≤ CRP <5     | 0.91 (0.58–1.45)    | 0.70                  | 0.92 (0.58–1.47)       | 0.73 |
| 5 ≤ CRP <10    | 1.10 (0.68–1.78)    | 0.70                  | 1.05 (0.64–1.72)       | 0.60 |
| 10 ≤ CRP       | 1.23 (0.78–1.95)    | 0.38                  | 1.14 (0.71–1.83)       | 0.60 |

| Opioids (mg/day) | Univariate analysis | Multivariate analysis |
|------------------|---------------------|-----------------------|
|                  |                     |                       |                       |
| 0                | —                   | —                     | 1.00 (reference)      |      |
| 0–60             | —                   | —                     | 3.29 (2.49–4.35)      | <0.001|
| ≥ 60             | —                   | —                     | 7.47 (5.39–10.36)     | <0.001|

To evaluate the relationship between the four CRP groups and breakthrough pain (presence or absence), ORs and 95% CIs were calculated after adjustments for independent variables, such as age, gender, metastasis, chemotherapy or targeted therapy within one month, the ECOG PS, and the opioid oral morphine milligram equivalent.
Moreover, neuropathic pain may have included chemotherapy-induced peripheral neuropathy and postherpetic neuralgia in this study, although the percentage of patients receiving chemotherapy or targeted therapy within one month was very small in this population. Furthermore, neuropathic pain has been associated with breakthrough pain.\textsuperscript{22–26} In this context, neither neuropathic nor breakthrough pain was associated with disease progression or serum levels of CRP.

Although the role of systemic inflammation in the genesis of multiple symptoms currently remains unclear, our previous findings and the present results indicate the clinical utility of high serum levels of CRP, for example, 10 mg/dL $\leq$ CRP, for predicting survival, the activities of daily living, physical symptoms, and psychological symptoms in patients with advanced cancer.\textsuperscript{9,11,14}

Hence, therapies to control systemic inflammation, for example, corticosteroids, nonsteroidal anti-inflammatory drugs, nutrition interventions, exercise, and a good sleep at night, appear to be vital for the management of pain, fatigue, and other physical and psychological symptoms related to cancer cachexia.\textsuperscript{27–30} These therapies may also prolong survival and improve the activities of daily living in patients with advanced cancer cachexia in palliative care settings. Further research is warranted.

This study has several limitations that need to be addressed. Measurement errors may be large, because this was a multicenter study in which multiple physicians participated. However, we measured symptoms according to clinical guidelines\textsuperscript{18} to improve the quality of data. In addition, the results obtained did not demonstrate a causal relationship between CRP levels and pain. There may have been unmeasured confounding factors and reverse causality. Elevated CRP levels may be a consequence of pain. Hence, causality remains unclear due to the characteristics of an observational study.

Moreover, the very high CRP group (10 mg/dL $\leq$ CRP) may have had coexisting acute infections or medical conditions. Nevertheless, the clinical implications of CRP remain unchanged, because these factors also aggravate clinical outcomes and deteriorate physical and psychological symptoms. In addition, the results of this study were influenced slightly by cancer treatments, including chemotherapy and radiotherapy, causing systemic inflammation, because all subjects were admitted to palliative care units after the cessation of cancer treatments.

Another limitation is that the effects of medical agents suppressing systemic inflammation, such as corticosteroids and nonsteroidal anti-inflammatory drugs, and adjuvant analgesics in addition to opioids, were not considered. Furthermore, pain may have comprised nociceptive pain, neuropathic pain, mixed nociceptive–neuropathic pain, breakthrough pain, and even chronic pain from sources other than cancer in this study. However, a comprehensive evaluation of pain is necessary and useful for both patients and physicians to measure the quality of life of patients in daily clinical practice.

**Conclusions**

The present results indicate that significant and direct relationships exist between CRP levels and pain in patients with advanced cancer cachexia. This study also describes the current implementation of opioid medication for cancer pain in palliative care units in Japan. Studies that target systemic inflammation and assess its impact on pain and other symptoms from the viewpoint of cancer cachexia are important. Further research is warranted in the near future.

**Authors’ Contributions**

Study concept and design were carried out by K.A., I.M., Y.H., M.M., and T.M. Collection and/or assembly of data were done by K.A., H.I., T.M., I.M., Y.H., S.O., N.Y., K.T., T.O., T.I., M.B., T.M., and M.M. Statistical analysis was performed by K.A., I.M., Y.H., and S.O. Data analysis and interpretation were done by K.A., I.M., Y.H., S.O., M.M., and T.M. Drafting of the article was by K.A. and S.O. Final approval of the article was carried out by K.A., H.I., T.M., I.M., Y.H., S.O., N.Y., K.T., T.O., T.I., M.B., T.M., and M.M.

**Acknowledgments**

This study was performed in the East-Asian collaborative cross-cultural study to elucidate the dying process. The participating study sites and site investigators in Japan were as follows: Satoshi Inoue, MD (Seirei Hospice, Seirei Mikatahara General Hospital), Kengo Imai, MD (Seirei Hospice, Seirei Mikatahara General Hospital), Hiroaki Tsukuura, MD, PhD (Department of Palliative Care, TUMS Urayasu Hospital), Toshibiro Yamauchi, MD (Seirei Hospice, Seirei Mikatahara General Hospital), Akemi Shirado Naito, MD (Department of Palliative Care Miyazaki Medical Association Hospital), Yu Uneno, MD (Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University), Akira Yoshioka, MD, PhD (Department of Oncology and Palliative Medicine, Mitsubishi Kyoto Hospital), Shuji Hiramoto, MD (Department of Oncology and Palliative Medicine, Mitsubishi Kyoto Hospital), Ayako
Kikuchi, MD (Department of Oncology and Palliative Medicine, Mitsubishi Kyoto Hospital), Tetsuo Hori, MD (Department of Respiratory Surgery, Mitsubishi Kyoto Hospital), Yosuke Matsuda, MD (Palliative Care Department, St. Luke’s International Hospital), Hiroyuki Kohara, MD, PhD (Kobe General Hospital), Hiromi Funaki, MD (Kobe General Hospital), Keiko Tanaka, MD, PhD (Department of Palliative Care Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital), Kozue Suzuki, MD (Department of Palliative Care Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital), Tatsuya Omi, MD (Department of Palliative Care, NTT Medical Center Tokyo), Yukari Azuma, MD (Department of Palliative Medicine, Osaka City General Hospital), Hirofumi Katayama, MD (Department of Palliative Medicine, Osaka City General Hospital), Hiroshi Ito, MD (Department of Palliative Medicine, Osaka City General Hospital), Nao Ikuta, MD (Department of Palliative Medicine, Osaka City General Hospital), Hirofumi Matsumoto, MD (Aso Iizuka Hospital/Transitional and Palliative Care), Kiyofumi Oya, MD (Aso Iizuka Hospital/Transitional and Palliative Care), Takeya Yamaguchi, MD (Aso Iizuka Hospital/Transitional and Palliative Care), Eri Matsumoto, MD (Aso Iizuka Hospital/Transitional and Palliative Care), Kiyosumi Oya, MD (Aso Iizuka Hospital/Transitional and Palliative Care), Takeya Yamaguchi, MD (Japan Community Health Care Organization Kyushu Hospital/Palliative Care), Tomonao Okamura, MD, MBA (Aso Iizuka Hospital/Transitional and Palliative Care), Hoshu Hashimoto, MD, MBA (Inoue Hospital/Internal Medicine), Shunsuke Kosugi, MD (Department of General Internal Medicine, Aso Iizuka Hospital), Nao Ikuta, MD (Department of Emergency Medicine, Osaka Red Cross Hospital), Yaichiro Matsumoto, MD (Department of Transitional and Palliative Care, Aso Iizuka Hospital), Takashi Ohmori, MD (Department of Transitional and Palliative Care, Aso Iizuka Hospital), Takehiro Nakai, MD (Immuno-Rheumatology Center, St Luke’s International Hospital), Takashi Ikei, MD (Department of Cardioiology, Aso Iizuka Hospital), Yuto Unoki, MD (Department of General Internal Medicine, Aso Iizuka Hospital), Kazuki Kitade, MD (Department of Orthopedic Surgery, Saga-Ken Medical Centre Koseikai), Shu Koito, MD (Department of General Internal Medicine, Aso Iizuka Hospital), Nanao Ishibashi, MD (Environmental Health and Safety Division, Environmental Health Department, Ministry of the Environment), Masaya Ebara, MD (TOShiba), Kosuke Kuwahara, MD (Department of General Internal Medicine, Aso Iizuka Hospital), Shohei Ueno, MD (Department of Hematology/Oncology, Japan Community Healthcare Organization Kyushu Hospital), Shunsuke Nakashima, MD (Oshima Clinic), Yuta Ishiyama, MD (Department of Transitional and Palliative Care, Aso Iizuka Hospital), Akihiro Sakashita, MD, PhD (Department of Palliative Medicine, Kobe University School of Medicine), Ryo Matsunuma, MD (Department of Palliative Medicine, Kobe University Graduate School of Medicine), Hana Takatsus, MD (Division of Palliative Care, Konan Medical Center), Takashi Yamaguchi, MD, PhD (Division of Palliative Care, Konan Medical Center), Satoko Ito, MD (Hospice, The Japan Baptist Hospital), Toru Terabayashi, MD (Hospice, The Japan Baptist Hospital), Jun Nakagawa, MD (Hospice, The Japan Baptist Hospital), Tetsuya Yamagita, MD, PhD (Hospice, The Japan Baptist Hospital), Akira Inoue, MD, PhD (Department of Palliative Medicine Tohoku University School of Medicine), Takahiro Yamaguchi, PhD (Professor of Biostatistics, Tohoku University Graduate School of Medicine), Mitsunori Miyashita, RN, PhD (Department of Palliative Nursing, Health Sciences, Tohoku University Graduate School of Medicine), Saran Yoshida, PhD (Graduate School of Education, Tohoku University), Yusuke Hiramatsu, MD, PhD (Department of Palliative Medicine Tohoku University School of Medicine), Hiroaki Watanabe, MD (Department of Palliative Care, Komaki City Hospital), Masayuki Ikenaga, MD (Hospice, Yodogawa Christian Hospital), Keiji Shimizu, MD, PhD (Department of Palliative Care Internal Medicine, Osaka General Hospital of West Japan Railway Company), Akira Hayakawa, MD, PhD (Hospice, Yodogawa Christian Hospital), Rina Kura, MD (Hospice, Yodogawa Christian Hospital), Takeru Okoshi, MD, PhD (Okoshi Nogominomori Clinic), Tomohiro Nishi, MD (Kawasaki Municipal Ida Hospital, Kawasaki Comprehensive Care Center), Kazuhiro Kosugi, MD (Department of Palliative Medicine, National Cancer Center Hospital East), Yasuhiro Shibata, MD (Kawasaki Municipal Ida Hospital, Kawasaki Comprehensive Care Center), Takayuki Hisanaga, MD (Department of Palliative Medicine, Tsukuba Medical Center Hospital), Takahiro Higashihata, MD, PhD (Department of General Medicine and Primary Care, Palliative Care Team, University of Tsukuba Hospital), Ritsuko Yabuki, MD (Department of Palliative Medicine, Tsukuba Medical Center Hospital), Shingo Hagihara, MD, PhD (Department of Palliative Medicine, Yuai Memorial Hospital), Miho Shimokawa, MD (Department of Palliative Medicine, Yuai Memorial Hospital), Shinji Sugita, MD (Department of Palliative Medicine, Yuai Memorial Hospital), Miho Shimokawa, MD
of Palliative Medicine, Tsukuba Medical Center Hospital), Satoshi Miyake, MD, PhD (Professor, Department of Clinical Oncology Graduate School of Medical and Dental Sciences Tokyo Medical and Dental University [TMDU]), Junko Nozato, MD (Specially Appointed Assistant Professor, Department of Internal Medicine, Palliative Care, Medical Hospital, TMDU), Tetsuji Iriyama, MD (Specially Appointed Assistant Professor, Department of Internal Medicine, Palliative Care, Medical Hospital, TMDU), Keisuke Kaneishi, MD, PhD (Department of Palliative Care Unit, JCHO Tokyo Shinjuku Medical Center), Yoshihisa Matsutomo, MD, PhD (Department of Palliative Medicine, National Cancer Center Hospital East), Ayumi Okizaki, PhD (Department of Palliative Medicine, National Cancer Center Hospital East), Yuki Sumazaki Watanabe, MD (Department of Palliative Medicine, National Cancer Center Hospital East), Yuko Uehara, MD (Department of Palliative Medicine, National Cancer Center Hospital East), Eriko Satomi, MD (Department of Palliative Medicine, National Cancer Center Hospital), Kaoru Nishijima, MD (Department of Palliative Medicine, Kobe University Graduate School of Medicine), Junichi Shimoinaba, MD (Department of Hospice Palliative Care, Eikoh Hospital), Ryoichi Nakahori, MD (Department of Palliative Care, Fukuoka Minato Home Medical Care Clinic), Takeshi Hirohashi, MD (Eiju General Hospital), Jun Hamano, MD, PhD (Assistant Professor, Faculty of Medicine, University of Tsukuba), Natsuki Kawashima, MD (Department of Palliative Medicine, Tsukuba Medical Center Hospital), Takashi Kawaguchi, PhD (Tokyo University of Pharmacy and Life Sciences Department of Practical Pharmacy), Megumi Uchida, MD, PhD (Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences), Ko Sato, MD, PhD (Hospice, Ise Municipal General Hospital), Yoichi Matsuda, MD, PhD (Department of Anesthesiology and Intensive Care Medicine/Osaka University Graduate School of Medicine), Satoru Tsumeto, MD, PhD (Professor, Department of Human Health Sciences, Graduate School of Medicine, Kyoto University Department of Palliative Medicine, Kyoto University Hospital), Sayaka Maeda, MD (Department of Palliative Medicine, Kyoto University Hospital), Yoshii Kizawa MD, PhD, FJSIM, DSBPMJ (Designated Professor and Chair, Department of Palliative Medicine, Kobe University School of Medicine), Hiroiuyki Otani, MD (Palliative Care Team, and Palliative and Supportive Care, National Kyushu Cancer Center).

Consent for Publication
All authors agree to this submission.

Availability of Data and Material
The data sets generated and/or analyzed during this study are not publicly available as sharing is not explicitly covered by patient consent.

Author Disclosure Statement
No competing financial interests exist.

Funding Information
This study was supported, in part, by a Grant-in-Aid from the Japan Hospice Palliative Care Foundation.

References
1. Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature 2008;454:436–444.
2. Fearon K, Strasser F, Anker SD, et al.: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol 2011;12:489–495.
3. Lippitz BE: Cytokine patterns in patients with cancer: A systematic review. Lancet Oncol 2013;14:218–228.
4. Candido J, Hagemann T: Cancer-related inflammation. J Clin Immunol 2013;33(Suppl. 1):79–84.
5. Diakos CI, Charles KA, McMillan DC, Clarke SJ: Cancer-related inflammation and treatment effectiveness. Lancet Oncol 2014;15:493–503.
6. Baracos VE, Martin L, Koeller, et al.: Cancer-associated cachexia. Nat Rev Dis Primers 2018;4:17105.
7. Laird BJ, Scott AC, Colvin LA, et al.: Cancer pain and its relationship to systemic inflammation: An exploratory study. Pain 2011;152:460–463.
8. Laird BJ, McMillan DC, Fayers P, et al.: The systemic inflammatory response and its relationship to pain and other symptoms in advanced cancer. Oncologist 2013;18:1050–1055.
9. Amano K, Maeda I, Morita T, et al.: Clinical implications of C-reactive protein as a prognostic marker in advanced cancer patients in palliative settings. J Pain Symptom Manage 2016;51:860–867.
10. Paulsen Ø, Laird B, Aass N, et al.: The relationship between pro-inflammatory cytokines and pain, appetite and fatigue in patients with advanced cancer. PLoS One 2017;12:e0177620.
11. Amano K, Maeda I, Morita T, et al.: C-reactive protein, symptoms and activity of daily living in patients with advanced cancer receiving palliative care. J Cachexia Sarcopenia Muscle 2017;8:457–465.
12. Kwekkeboom KL, Tostrud L, Costanzo E, et al.: The role of inflammation in the pain, fatigue, and sleep disturbance symptom cluster in advanced cancer. J Pain Symptom Manage 2018;55:1286–1295.
13. Miranda DO, Anatriello E, Azevedo LR, et al.: Elevated serum levels of proinflammatory cytokines potentially correlate with depression and anxiety in colorectal cancer patients in different stages of the antitumor therapy. Cytokine 2018;104:72–77.
14. Amano K, Hatano Y, Matsuda Y, et al.: C-reactive protein, delirium, and other psychological symptoms among patients with advanced cancer. JSM Clin Rep 2020;5:42–51.
15. Laird BJ, Scott AC, Colvin LA, et al.: Pain, depression, and fatigue as a symptom cluster in advanced cancer. J Pain Symptom Manage 2011;42:1–11.
16. Oken MM, Creech RH, Tormey DC, et al.: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–655.
17. Sakurai H, Miyashita M, Imai K, et al.: Validation of the integrated palliative care outcome scale (IPOS)—Japanese version. Jpn J Clin Oncol 2019;49:257–262.
18. Clinical Guidelines for Cancer Pain Management, 2nd ed. Japanese Society for Palliative Medicine. Tokyo Japan: KANEHARA and Co., Ltd., 2014; www.jspm.ne.jp/guidelines/pain/2014/index.php (Last accessed January 3, 2021).
19. Bland M: An Introduction to Medical Statistics, 3rd ed. Oxford, UK: Oxford University Press, 2000.
20. Yamaguchi T, Morita T, Nitto A, et al.: Establishing cutoff points for defining symptom severity using the Edmonton symptom assessment system-revised Japanese version. J Pain Symptom Manage 2016;51: 292–297.
21. Murtagh FE, Ramsenthaler C, Firth A, et al.: A brief, patient- and proxy-reported outcome measure in advanced illness: Validity, reliability and responsiveness of the Integrated Palliative care Outcome Scale (IPOS). Palliat Med 2019;33:1045–1057.
22. Bennett MI, Raymond C, Hjermstad M, et al.: Prevalence and aetiology of neuropathic pain in cancer patients: A systematic review. Pain 2012;153: 359–365.
23. Yoon SY, Oh J: Neuropathic cancer pain: Prevalence, pathophysiology, and management. Korean J Intern Med 2018;33:1058–1069.
24. Bennett MI, Kaasa S, Barke A, et al.: The IASP classification of chronic pain for ICD-11: Chronic cancer-related pain. Pain 2019;160:38–44.
25. Scholz J, Finnerup NB, Attal N, et al.: The IASP classification of chronic pain for ICD-11: Chronic neuropathic pain. Pain 2019;160:53–59.
26. Edwards HL, Mulvey MR, Bennett MI: Cancer-related neuropathic pain. Cancers 2019;11:373.
27. Roxburgh CSD, McMillan DC: Cancer and systemic inflammation: Treat the tumour and treat the host. Br J Cancer 2014;110:1409–1412.
28. Garcia JM, Shamiyan TA: Nonsteroidal anti-inflammatory drugs in patients with anorexia-cachexia syndrome associated with malignancy and its treatments. Am J Med 2017;130:1033–1036.
29. Advani SM, Advani PG, VonWille HM, Jafri SH: Pharmacological management of cachexia in adult cancer patients: A systematic review of clinical trials. BMC Cancer 2018;18:1174.
30. Roeland EJ, Bohlke K, Baracos VE, et al.: Management of cancer cachexia: ASCO guideline. J Clin Oncol 2020;38:2438–2453.

Cite this article as: Amano K, Ishiki H, Miura T, Maeda I, Hatano Y, Oyamada S, Yokomichi N, Tagami K, Odagiri T, Ito T, Baba M, Morita T, and Mori M; on behalf of the East-Asian Collaborative Cross-Cultural Study to Elucidate the Dying Process (EASED) Investigators (2021) C-reactive protein and its relationship with pain in patients with advanced cancer cachexia: Secondary cross-sectional analysis of a multicenter prospective cohort study, Palliative Medicine Reports 2:1, 122–131, DOI: 10.1089/pmr.2021.0004.

Abbreviations Used
CI = confidence interval
CRP = C-reactive protein
ECOG PS = Eastern Cooperative Oncology Group Performance Status
IPOS = integrated palliative care outcome scale
IQR = interquartile range
NRS = numerical rating scale
OR = odds ratio
SD = standard deviation

Publish in Palliative Medicine Reports
- Immediate, unrestricted online access
- Rigorous peer review
- Compliance with open access mandates
- Authors retain copyright
- Highly indexed
- Targeted email marketing

liebertpub.com/pmr